This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Immunogenicity & PersistenceTRUMENBA is the only MenB vaccine with confirmed cross-reactivity against diverse strains1
TRUMENBA demonstrated robust immune response against 14 MenB strains found in the US and Europe1
TRUMENBA is the only MenB vaccine approved based on testing against 4 MenB strains representative of prevalent strains in the United States1Study 1 was a Phase 3, randomized, active-controlled, observer-blinded trial in adolescents 10 to 25 years of age (n=1057). Study 2 was a Phase 3, randomized, active-controlled, observer-blinded trial in adolescents 10 to 18 years of age (n=2693), and study 3 was a Phase 3, randomized, placebo-controlled, observer-blinded trial in young adults 18 to 25 years of age (n=2471). Studies 1 and 2 were conducted in the United States, Canada, and Europe. In study 1, subjects received 2 doses of TRUMENBA on a 0- and 6-month schedule, and in studies 2 and 3, subjects received 3 doses of TRUMENBA on a 0-, 2-, and 6-month schedule.1,2To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline titer of ≥1:4, an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.1,21:8 for A07, A15, A29, B03, B09, B15, and B16; 1:16 for A06, A12, and A19.1,2TRUMENBA can help protect adolescents and young adults during their peak risk years3,4fHbp=factor H binding protein; hSBA=serum bactericidal activity using human complement; MenB=serogroup B meningococcal disease.Title
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.
References:1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 2. Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377(24):2349-2362. 3. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for Infectious Diseases. Accessed April 1, 2021. https://www.nfid.org/wpcontent/uploads/2019/08/meningococcal-b-report.pdf. 4. Data on file. Clinical Study Report Protocol B1971033: Table 20. Pfizer Inc., New York, NY. 5. Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatr Infect Dis Soc. 2016;5(2):152-160. 6. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed April 1, 2021. 7. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 8. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 9. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130.
Efficacy & Safety Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
Find out about TruSupport Loading
Why adolescents and young adults?

Typical adolescent and young adult behaviors increase MenB risk.6-9

Learn more about MenB Loading
The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.1,2

See the scienceLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TRU-USA-3171
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.